'SynthoGen', a Manchester-based biotech startup, has closed a £85 million Series B funding round to scale its proprietary platform for synthetic protein production, aimed at the sustainable food and pharmaceutical sectors.
The company's technology uses engineered microbes to "brew" complex proteins that would otherwise require intensive animal farming or expensive chemical synthesis. The funding round was led by a consortium of European and US venture firms.
"Manchester is proving itself to be a powerhouse for deep tech," said the SynthoGen CEO. "This capital allows us to move from the lab to industrial-scale manufacturing within the next 18 months."
The startup plans to open a 50,000 square foot 'bio-foundry' in the Greater Manchester area, creating over 200 highly skilled jobs in the process.
